PMC:7546716 / 33518-33738 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T615","span":{"begin":9,"end":11},"obj":"Body_part"},{"id":"T616","span":{"begin":26,"end":34},"obj":"Body_part"}],"attributes":[{"id":"A615","pred":"fma_id","subj":"T615","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A616","pred":"fma_id","subj":"T616","obj":"http://purl.org/sig/ont/fma/fma62871"}],"text":"The anti-IL-33 monoclonal antibody, MEDI3506, has also been included among possible therapies for the treatment of hospitalised patients with COVID-19 and is currently being tested in a phase 2 adaptive platform study.91"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T201","span":{"begin":142,"end":150},"obj":"Disease"}],"attributes":[{"id":"A201","pred":"mondo_id","subj":"T201","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"The anti-IL-33 monoclonal antibody, MEDI3506, has also been included among possible therapies for the treatment of hospitalised patients with COVID-19 and is currently being tested in a phase 2 adaptive platform study.91"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T455","span":{"begin":46,"end":49},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T456","span":{"begin":174,"end":180},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T457","span":{"begin":184,"end":185},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"The anti-IL-33 monoclonal antibody, MEDI3506, has also been included among possible therapies for the treatment of hospitalised patients with COVID-19 and is currently being tested in a phase 2 adaptive platform study.91"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T486","span":{"begin":9,"end":11},"obj":"Chemical"}],"attributes":[{"id":"A486","pred":"chebi_id","subj":"T486","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A487","pred":"chebi_id","subj":"T486","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"}],"text":"The anti-IL-33 monoclonal antibody, MEDI3506, has also been included among possible therapies for the treatment of hospitalised patients with COVID-19 and is currently being tested in a phase 2 adaptive platform study.91"}

{"project":"LitCovid-sentences","denotations":[{"id":"T137","span":{"begin":0,"end":220},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The anti-IL-33 monoclonal antibody, MEDI3506, has also been included among possible therapies for the treatment of hospitalised patients with COVID-19 and is currently being tested in a phase 2 adaptive platform study.91"}

{"project":"LitCovid-PubTator","denotations":[{"id":"1391","span":{"begin":9,"end":14},"obj":"Gene"},{"id":"1399","span":{"begin":128,"end":136},"obj":"Species"},{"id":"1415","span":{"begin":142,"end":150},"obj":"Disease"}],"attributes":[{"id":"A1391","pred":"tao:has_database_id","subj":"1391","obj":"Gene:90865"},{"id":"A1399","pred":"tao:has_database_id","subj":"1399","obj":"Tax:9606"},{"id":"A1415","pred":"tao:has_database_id","subj":"1415","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The anti-IL-33 monoclonal antibody, MEDI3506, has also been included among possible therapies for the treatment of hospitalised patients with COVID-19 and is currently being tested in a phase 2 adaptive platform study.91"}

{"project":"2_test","denotations":[{"id":"33073244-32736596-66244651","span":{"begin":218,"end":220},"obj":"32736596"}],"text":"The anti-IL-33 monoclonal antibody, MEDI3506, has also been included among possible therapies for the treatment of hospitalised patients with COVID-19 and is currently being tested in a phase 2 adaptive platform study.91"}